Ghana vs Zimbabwe: Average cost of drugs for extensively drug-resistant tuberculosis
Ghana
800 constant 2022 US$
in 2024
Zimbabwe
852 constant 2022 US$
in 2023
Ghana rank
47th
Zimbabwe rank
45th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Ghana
- Zimbabwe
How they compare
Zimbabwe currently reports 852 constant 2022 US$ against 800 constant 2022 US$ in Ghana, a difference of 52 constant 2022 US$.
That makes Zimbabwe's figure about 1.1 times Ghana's.
The two have swapped places 2 times across 5 shared years of data; in 2018 it was Zimbabwe ahead.
Ghana ranks 47th and Zimbabwe ranks 45th of 56 countries.
Across the 2 decades both report, Ghana averaged higher in 1 and Zimbabwe in 1.
Head to head by decade
| Decade | Ghana | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 7,268 constant 2022 US$ | 5,268 constant 2022 US$ | Zimbabwe |
| 2020s | 1,577 constant 2022 US$ | 917.33 constant 2022 US$ | 659.33 constant 2022 US$ | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Ghana or Zimbabwe?
- Zimbabwe, at 852 constant 2022 US$ against 800 constant 2022 US$ in Ghana as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Ghana and Zimbabwe?
- 52 constant 2022 US$, with Zimbabwe ahead.
- How many years of comparable data are there for Ghana and Zimbabwe?
- 5 years are reported by both, from 2018 to 2023.
- How do Ghana and Zimbabwe rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Ghana ranks 47th and Zimbabwe ranks 45th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.